Drug · CHEMBL916
TIROFIBAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TIROFIBAN. Drugs and targets, record CHEMBL916. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL916
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ITGA2B | Integrin alpha-IIb/beta-3 | Integrin alpha-IIb/beta-3 inhibitor | INHIBITOR | https://conductscience.org/library/genes/3674 |
| ITGB3 | Integrin alpha-IIb/beta-3 | Integrin alpha-IIb/beta-3 inhibitor | INHIBITOR | https://conductscience.org/library/genes/3690 |
Source ChEMBL
Diseases9
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| ischemic stroke | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_1060198 |
| myocardial infarction | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
| acute coronary syndrome | Approval | TTD | 4 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005542 |
| stroke disorder | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005098 |
| subarachnoid hemorrhage | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005099 |
| acute myocardial infarction | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004781 |
| coronary artery disorder | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005010 |
| kidney failure | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001106 |
| Recurrent thrombophlebitis | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=HP_0004419 |
Source Open Targets
Trials60
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01522417 | Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention | Phase 2 | 535 | 2021-04-20 | tirofiban | Its name | ClinicalTrials.gov |
| NCT00445263 | Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation | Phase 4 | 170 | 2015-02-09 | tirofiban | Its name | ClinicalTrials.gov |
| NCT03114995 | Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients | Phase 4 | 140 | 2018-06-08 | tirofiban | Its name | ClinicalTrials.gov |
| NCT03691727 | Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM) | Phase 1/2 | 30 | 2021-10-04 | tirofiban | Its name | ClinicalTrials.gov |
| NCT03048019 | Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention | 10 | 2023-12-11 | tirofiban | Its name | ClinicalTrials.gov | |
| NCT06319846 | Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4） | Phase 3 | 4,674 | tirofiban | Its name | ClinicalTrials.gov | |
| NCT00251576 | Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) | Phase 3 | 4,497 | tirofiban | Its name | ClinicalTrials.gov | |
| NCT01696110 | BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial. | Phase 4 | 2,194 | tirofiban | Its name | ClinicalTrials.gov | |
| NCT00566891 | Safety of High-dose Tirofiban During Coronary Angioplasty | Phase 4 | 2,000 | tirofiban | Its name | ClinicalTrials.gov | |
| NCT06265051 | Tirofiban After Successful MT Recanalization in AIS | Phase 2/3 | 1,380 | tirofiban | Its name | ClinicalTrials.gov |
1 to 10 of 60
See all 60 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Early Invasive Strategy vs Delayed Invasive Strategy: Mortality, Myocardial Infarction and Revascularization in Emergency | 2 of 83 | 21 of 86 | 169 | NCT00445263 | Trial comparisons |
| Early Invasive Strategy vs Delayed Invasive Strategy: serious adverse events | 2 of 83 | 1 of 86 | 169 | NCT00445263 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | 1 of 18 | 4 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | 2 of 18 | 1 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: deaths from any cause | 1 of 18 | 0 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: serious adverse events | 18 of 18 | 12 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Therapy vs Cangrelor Therapy: deaths from any cause | 0 of 5 | 0 of 5 | 10 | NCT03048019 | Trial comparisons |
| Tirofiban Therapy vs Cangrelor Therapy: serious adverse events | 1 of 5 | 0 of 5 | 10 | NCT03048019 | Trial comparisons |
Papers from its trials66
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 1 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL916
GET https://conductscience.org/api/drugs/v1/CHEMBL916/trials?page=2